Antithrombotic treatment for the preservation and enhancement of myocardial perfusion in chronic coronary artery disease

Fibrinolysis and Proteolysis

Volumn 11, Issue SUPPL. 1, 1997, Pages 119-123

  Leschke, M ^a   Schoebel, F C ^a   Heins, M ^b   Strauer, B E ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Institut für Klinische Chemie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOGEN; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW MOLECULAR WEIGHT HEPARIN; UROKINASE;

ATHEROSCLEROTIC PLAQUE; BLOOD RHEOLOGY; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DRUG EFFICACY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0030697245     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80035-5     Document Type: Conference Paper

References (26)

1. Brown B G, Xue-Qiao, Sacco D E, Albers J J. Lipid lowering and plaque regression - new insights into the prevention of coronary plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-1791
2. Treasure C B, Klein J I, Weintraub W S, Talley J, Stillablower M E, Kosinski A S, Zhang J, Boccuzzi S J, Cedarholm J C, Alexander W. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-487.
3. Could K L, Ormish D, Sikerwitz Z et al. Changes in myocardial perfusion abnormalities by poilron emission tomography after long-term, intense risk factor modification. JAMA 1995; 274: 894-901.
4. Fuster V, Badimon L, Badimon J, Chesebro J. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326: 242-250.
5. Davies M J, Bland J M, Hangartner J R W, Angelini A, Thomas A C. Factors influencing the presence or absence of acute coronary syndromes in sudden ischemic death. Eur Heart J 1989; 10: 203-208.
6. Itoh A, Miyazaki S, Nonogi H, Daikoku S, Haze K. Angioscopic prediction of successful dilation and of restenosis in percutaneous transluminal coronary angioplasty - Significance of the yellow plaque. Circulation 1995; 91: 1389-1396.
7. Koenig W, Ernst E. The possible role of hemorheology in atherothrombogenesis. Atherosclerosis 1992; 94: 93-107.
8. Ernst E, Resch L. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-963.
9. Ceriello A, Pirisi M, Giacomello R, Stel G, Falleti E, Motz E, Lizzio S, Gonano F. Fibrinogen plasma levels as a marker of thrombin activation: New insights on the role of fibrinogen as a cardiovascular risk factor. Thromb Haemost 1994; 71: 593-595.
10. Stein D, Schoebel F C, Heins M, Withold W, Pels K, Jax T, Reinauer H, Leschke M, Strauer B E. Activation of the fibrinolytic system in patiens with hyperfibrinogenemia and coronary artery disease. Ann Haematol 1995; 70 (Suppl. I): 359.
11. Ericsson C G, Hamsten A, Nilson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849-853.
12. Brown B G, Bolson E L, Pierce C D, Petersen R B, Wong M, Dodge H T. Progression of native coronary atherosclerosis is not altered by aspirin plus dipyridamole. Circulation 1983; 68 (Suppl. III): 398.
13. Chesebro J H, Webster M W I, Smith H C, Frye R L, Holmes D R, Reeder G S, Bresnahan D R, Nishimura A, Clements I P, Bardsley W T, Grill D E, Fuster V. Antiplatelet therapy in coronary disease progression: Reduced infarction and new lesion formation. Circulation 1989; 80 (Suppl. II): 266.
14. Veen G, Meyer A, Verbeugt F W A, Werter C P J P, Swart H de, Lie K I, Pol J M J van der, Michels H R, Eenige M J van. Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: Angiographic results of the APRICOT Study. J Am Coll Cardiol 1993; 22: 1755-1762.
15. Ranke C, Hecker H, Creutzig A, Alexander K. Dose-dependent effect of aspirin on carotid atherosclerosis. Circulation 1993; 87: 1873-1879.
16. Nakagawa S, Hanada Y, Koiwaya Y, Tanaka K. Angiographic features in prolonged anticoagulation: Role of ruptured atheromatous plaque and adherent thrombus in acute myocardial infarction in vivo. Circulation 1988; 78: 1335-1344.
17. Fujita M, Sasayama S, Asanoi H, Nakajima H, Sakai O, Ohno A. Improvement of treadmill capacity and collateral circulation as a result of exercise with heparin pretreatment. Circulation 1988; 77: 1022-1029.
18. Melandri G, Semprini F, Cervi V, Candiotti N, Palazzini E, Branzi A, Magnami B. Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris: a double-blind, randomized, placebo-controlled trial. Circulation 1993; 88: 2517-2523.
19. Quyyumi A A, Diodati J G, Lakatos E E, Bonow R O, Epstein S E. Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: A pilot study. J Am Coll Cardiol 1993; 22: 635-641.
20. Wolf R, Lichtlen P R. Die Beziehung zwischen Plasmafibrinogen und der Funktion koronarer Kollateralgefäße. Z Kardiol 1995; 84: 348-359.
21. Leschke M, Höffken H, Motz W, Blanke H, Schoebel F C, Strauer B E. Chronisch-intermittierende Urokinasetherapie bei therapierefraktärer Angina pectoris. Dtsch Med Wschr 1992; 117: 81-87.
22. Leschke M, Schoebel F C, Mecklenbeck W, Stein D, Jax T W, Strauer B E. Long-term intermittent urokinase therapy in end-stage coronary artery disease and refractory angina pectoris: A randomized dose-response trial. J Am Coll Cardiol 1996; 27: 575-584.
23. Schoebel F C, Leschke M, Stein D, Heins M, Pels K, Jax T W, Strauer B E. Chronic-intermittent urokinase therapy in refractory angina pectoris. Fibrinolysis 1995; 9(Suppl 1): 121-125.
24. Gordon R J, Snyder G K, Tritel H, Taylor W J. Potential significance of plasma viscosity and hematocrit variations in myocardial ischemia. Am Heart J 1974; 87: 175-182.
25. Schmid-Schönbein H. Interaction of vasomotion and blood rheology in hemodynamics. In: Lowe G D O, Barbendel J C, Forbes C D eds. Clinical aspects of blood viscosity and cell deformability. Berlin: Springer 1981: 49-65.
26. Smith E B, Keen G A, Grant A, Stirk C. Fate of fibrinogen in human arterial intima. Arteriosclerosis 1990; 10: 263-275.